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ABSTRACT
Objectives Genome-wide association studies in 
rheumatoid arthritis (RA) have failed to examine the 
FCGR gene cluster because of the confounding effects 
of segmental duplication. This study aimed to replicate 
previous candidate gene studies that had identifi ed a 
signifi cant association between the FCGR3A-158V allele 
and RA and then sought to estimate specifi c subgroup 
effects.
Methods FCGR3A-158F/V genotyping was undertaken 
in a UK Caucasian replication cohort comprising 2049 
patients with RA and 1156 controls. Subgroup analyses 
assessing the magnitude of association according 
to gender and autoantibody (rheumatoid factor (RF) 
and cyclic citrullinated peptide (CCP)) status were 
undertaken in a pooled cohort of 2963 patients with RA 
and 1731 controls. Logistic regression was used to test 
for interaction between FCGR3A and HLA-DRB1 shared 
epitope (SE) alleles.
Results In the combined RA cohort, borderline 
association with homozygosity was found for the 
FCGR3A-158V allele (OR 1.2, p=0.05), which was 
stronger in men (OR 1.7, p=0.01). Stratifi cation by 
autoantibody status showed an increased risk in RF 
and CCP positive RA. Analysis of the FCGR3A-158V and 
HLA-DRB1 SE interaction revealed roles for both genes 
in susceptibility to autoantibody positive RA, with no 
evidence of interaction.
Conclusions FCGR3A is a risk factor for the 
development of autoantibody positive RA, particularly in 
men, with evidence of a multiplicative effect with HLA-
DRB1 SE.
INTRODUCTION
Recent genome-wide association studies (GWAS) 
in rheumatoid arthritis (RA) have been highly 
successful in both the confi rmation of known 
genetic associations and in highlighting new loci/
immunological pathways that warrant further 
investigation.1 However, GWAS are limited by 
the technologies they employ. Those technologies 
based on probe hybridisation rely on each single 
nucleotide polymorphism (SNP) having a unique 
fl anking sequence. SNPs in segmental duplications, 
which comprise ~5% of the genome,2 frequently 
fail quality controls owing to the presence of multi-
ple paralogs, leading to poor coverage of duplicated 
regions in GWAS.
The FCGR locus on chromosome 1q23 has arisen 
through a series of duplication events.3 The best 
characterised SNP in terms of the pathogenesis of 
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RA is the non-synonymous 158 V/F polymorphism 
in FCGR3A (rs396991), which substitutes a valine 
for a phenylalanine at amino acid position 158, 
thereby increasing the affi nity of FcγRIIIa for IgG1 
and IgG3.4 We and other groups have previously 
found an association between the higher affi nity 
V allele and RA,5–9 particularly in subgroups with 
more severe disease marked by nodules,8–10 and 
have discussed potential biological pathways that 
may be upregulated by this SNP. Some groups have 
been either unable to detect similar associations, 
possibly due to cohort size, or have identifi ed an 
association with the alternative allele.11–14
The FCGR locus has poor SNP coverage on the 
main commercial arrays owing to the presence of 
homologous sequence paralogs. For FCGR3A and 
FCGR3B, none of the array-based assays on the 
commonly used commercial arrays (Affymetrix 
5.0, 6.0, Illumina Human Map 300, 550, 650) are 
gene-specifi c. Thus, despite advances in genotyping 
technologies, the FCGR locus can currently only be 
investigated using well-designed conventional low 
to medium throughput technologies.
The aim of the current study was to re-evaluate 
the association of FCGR3A with RA by undertaking 
a replication study in a large UK Caucasian popula-
tion and a meta-analysis of previous work. We pre-
viously demonstrated a multiplicative joint effect 
with the HLA-DRB1 shared epitope (SE). Given 
the strong association between HLA-DRB1 SE and 
cyclic citrullinated peptide (CCP) autoantibodies,15 
we also undertook a series of subgroup analyses 
stratifying for autoantibody status.
PATIENTS AND METHODS
Patients with RA aged ≥18 years of age at disease 
onset (n=834) were recruited from the Yorkshire 
Early Arthritis Register (YEAR). An additional 
1215 patients were recruited from the general 
rheumatology outpatients in Leeds or through 
the Biologics in Rheumatoid Arthritis Genetics 
and Genomics Study Syndicate (BRAGGSS), as 
described previously.16 All cases were Caucasian 
of Northern European descent and fulfi lled the 
1987 American College of Rheumatology clas-
sifi cation criteria.17 Healthy controls were a 
combination of blood donors (n=235) and gen-
eral population controls recruited from Sheffi eld 
(n=921).18 19 An additional 914 patients with RA 
and 575 control subjects from our previous stud-
ies were included in the combined and subgroup 
analyses.8 9
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with RA and 1731 controls. For the combined RA cohort, 69% 
of the patients were women, 76% were HLA-DRB1 SE positive, 
75% were IgM RF positive and 73% were positive for CCP anti-
bodies. The gender was known for 1551 control subjects, 60% 
of whom were women.
Association of FCGR3A with rheumatoid arthritis
There was no departure from Hardy–Weinberg equilibrium in 
the control group. Assuming a recessive model, the effect size 
for FCGR3A-158V was reduced in the replication cohort and 
failed to reach statistical signifi cance (OR 1.1, 95% CI 0.9 to 
1.4; table 1), but the estimate was consistent with an increase 
in risk.
When the replication study was combined with the original 
cohort, homozygosity for the FCGR3A-158V allele showed bor-
derline signifi cance with RA (OR 1.2, 95% CI 1.0 to 1.5; table 1). 
The strength of the association was found to be greater in men 
(table 1), as previously reported by others.7 The association was 
also greater in those patients harbouring autoantibodies (CCP 
and/or IgM RF). An increased frequency of homozygosity for 
the FCGR3A-158V allele was observed in both RF positive and 
negative RA, but this was only statistically signifi cant in the RF 
positive subgroup (OR 1.3, 95% CI 1.0 to 1.6, p=0.03), most 
likely as a result of increased sample size and statistical power. 
However, an increased frequency of FCGR3A-158V homozy-
gotes was only observed in the CCP positive RA group (OR 
1.3, 95% CI 1.0 to 1.6, p=0.05), with an estimated OR of 1.0 
in the CCP negative group (table 1). No statistically signifi cant 
difference in autoantibody status between men and women was 
observed.
Meta-analysis
Data from 5320 cases of RA and 4558 healthy controls were 
available. There was no evidence of signifi cant population 
hetero geneity. The I2 statistic of 0% suggested that all variabil-
ity in effect estimates was due to sampling error within studies. 
We found that homozygosity for the V allele was signifi cantly 
associated with disease susceptibility (fi gure 1A, p=0.003), par-
ticularly in CCP positive RA (fi gure 1B, p=0.004).
Genotyping
FCGR3A genotyping (rs396991) was carried out using a validated 
single-stranded conformational polymorphism (SSCP) assay or, 
alternatively, by the direct sequencing of the same PCR prod-
uct.9 HLA-DRB1 typing and SE classifi cation was undertaken as 
previously described.9
Immunoassays
The majority of RA cases were recruited from NHS rheuma-
tology clinics throughout the UK and IgM rheumatoid factor 
(RF) status was measured using standard nephelometric assays. 
Patients who had ever had titres ≥40 units/μl were defi ned as 
RF positive. The presence of CCP antibodies was documented 
at a single time point for a proportion of the patients (n=1452) 
included in both the original and replication studies using the 
commercially available DIASTAT anti-CCP ELISA (Axis-Shield 
Diagnostics, Cambridgeshre, UK) or the ELiA CCP kit on an 
ImmunoCAP 100 (Phadia AB, Uppsala, Sweden). Patients who 
had a titre of ≥5.5 units/ml or ≥10 units/ml for the two assays, 
respectively, were defi ned as CCP positive.
Statistical analysis
Power calculations (power 80%, signifi cance 5%) indicated that 
the replication study had suffi cient power to detect an asso-
ciation between FCGR3A-158V and RA with an OR of 1.45, 
assuming a recessive model. Statistical analyses were performed 
using the SPSS 13.0 statistical package for Windows (Chicago, 
Illinois, USA). Data from the combined cohorts were stratifi ed 
according to gender and the presence of autoantibodies (RF and 
CCP). ORs and their 95% CI were calculated for the effect of 
the FCGR3A-158VV genotype on risk compared with alterna-
tive genotypes (ie, recessive model). The χ2 test was used for 
statistical comparisons and p values <0.05 were considered sta-
tistically signifi cant throughout.
The possibility of an interaction between FCGR3A and the 
HLA-DRB1 SE was formally tested, within a logistic regression 
framework, by performing a test for interaction (departure from 
a multiplicative joint effect) using the Stata statistical software 
release 10.0 (Stata Corporation, College Station, Texas, USA). 
Departure from an additive joint effect was investigated by cal-
culating the relative excess risk due to interaction (RERI) and 
hence (if RERI >0) the attributable proportion (AP) of risk due 
to interaction. The test was based on standard error estimates 
obtained from Taylor series expansion.20
For the meta-analysis, we searched PubMed for associa-
tion studies using the terms ‘FCGRIIIa’, ‘RA’, ‘Rheumatoid’, 
‘Arthritis’, ‘FCGR’, ‘Fcgamma’ and using references retrieved 
from these manuscripts. The meta-analyses were restricted to 
studies that specifi ed Caucasian ethnicity in the patients and 
controls. Seven studies fi tted the criteria for the meta-analy-
sis, resulting in a total of 5320 cases of RA and 4458 controls. 
Random effects models were used to perform the meta-analyses 
under a recessive model. Heterogeneity was investigated using 
I2, which describes the proportion of total variation in study esti-
mates that is due to heterogeneity and by Cochran’s Q-statistic. 
A meta-analysis stratifi ed by autoantibody status was performed 
for studies which reported the relevant data.
RESULTS
The replication study comprised 2049 subjects with RA and 
1156 controls who had not previously been genotyped. The sub-
analyses were undertaken on a combined cohort that included 
previously genotyped subjects and comprised 2963 patients 
Table 1 FCGR3A genotype frequencies and subgroup analyses
Cohort
FCGR3A  158
OR (95% CI, p value)*FF FV VV
Replication
 Controls (n=1156) 525 (0.45) 515 (0.45) 116 (0.10)
 RA (n=2049) 918 (0.45) 903 (0.44) 228 (0.11) 1.1 (0.9 to 1.4, p=0.3)
Combined
 Controls (n=1731) 798 (0.46) 760 (0.44) 173 (0.10)
 RA (n=2963) 1311 (0.44) 1300 (0.44) 352 (0.12) 1.2 (1.0 to 1.5, p=0.05)
Subgroup
 RF+ (n=2005) 881 (0.44) 878 (0.44) 246 (0.12) 1.3 (1.0 to 1.6, p=0.03)
 RF− (n=650) 283 (0.44) 292 (0.45) 75 (0.12) 1.2 (0.9 to 1.6, p=0.3)
 CCP+ (n=1071) 469 (0.44) 469 (0.44) 133 (0.12) 1.3 (1.0 to 1.6, p=0.05)
 CCP− (n=381) 164 (0.43) 180 (0.47) 37 (0.10) 1.0 (0.7 to 1.4, p=0.9)
Women
 Controls (n=922) 425 (0.46) 393 (0.43) 104 (0.11)
 RA (n=2060) 888 (0.43) 926 (0.45) 246 (0.12) 1.1 (0.8 to 1.4, p=0.6)
Men
 Controls (n=629) 295 (0.47) 284 (0.45) 50 (0.08)
 RA (n=755) 349 (0.46) 311 (0.41) 95 (0.13) 1.7 (1.2 to 2.4, p=0.01)
*A recessive model was used to estimate the relative risk of homozygosity for the 
FCGR3A-158V allele.
CCP, cyclic citrullinated peptide; RA, rheumatoid arthritis; RF, rheumatoid factor.
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revealed that RA subgroups with either RF or CCP autoantibod-
ies demonstrated an additive/multiplicative joint effect between 
both FCGR3A and HLA-DRB1 SE alleles, with no evidence of 
statistical interaction. Much larger studies will be required to 
identify suffi cient numbers of subjects with RA positive for a 
single autoantibody to determine whether the primary associa-
tion is downstream of RF or CCP autoantibodies, which may 
ligate different FcγRs.
Segmental duplications and copy number variants are mecha-
nistically linked.23 A recent report has indicated that both FCGR3A 
and FCGR3B are subject to independent copy number variation.24 
To date, there is no evidence that FCGR3A copy number is asso-
ciated with RA per se. The impact of copy number variation on 
FCGR3A allelic association has been shown to be slight in a Dutch 
Joint effect of FCGR3A and the HLA-DRB1 shared epitope
We calculated the risk of developing RA conferred by combinations 
of homozygosity for the FCGR3A-158V allele and the  presence of 
a HLA-DRB1 SE allele (table 2). The data were consistent with 
either an additive or multiplicative joint effect, with no evidence 
of an interaction between these two genetic loci (table 2). The 
increased risk to FCGR3A and HLA-DRB1 SE positive  individuals 
was strong (OR 5.1, 95% CI 3.6 to 7.1, p<0.0001), particularly in 
the RF positive (OR 7.0, 95% CI 4.9 to 9.9, p<0.0001) and CCP 
positive (OR 8.4, 95% CI 5.7 to 12.4, p<0.0001) subgroups.
DISCUSSION
We have previously demonstrated and confi rmed an associa-
tion with homozygosity for the FCGR3A-158V allele in estab-
lished RA cohorts. Our replication study showed the same trend 
towards an increase in FCGR3A-158VV genotype frequency and 
the combined analysis demonstrated borderline statistical sig-
nifi cance, with an OR of 1.2 compared with 1.5 in our previous 
studies.9 To detect a more modest association with an OR of 
1.2, which is comparable with other non-MHC genetic loci in 
RA, 4794 cases and controls would have been required which 
were not available for the current study. A meta-analysis of 
5320 patients with RA and 4558 healthy controls was therefore 
undertaken (fi gure 1) and confi rmed the association of FCGR3A-
158VV with RA (OR 1.2).
Emerging data suggest that different genetic and environ-
mental associations and thus pathogenic mechanisms may be 
observed in autoantibody positive and negative RA.21 This is 
of particular importance with respect to FCGR3A, since homo-
zygosity for the high affi nity variant may only be of functional 
signifi cance in the subgroup of patients with RA with either IgG 
antibodies (CCP) or IgG-containing immune complexes (RF). The 
presence of a higher affi nity activating receptor may enhance 
immune complex binding, thereby stimulating proinfl ammatory 
mediator release at lower concentrations. Indeed, FcγRIIIa has 
been implicated as a major trigger for release of tumour necrosis 
factor from human macrophages following the binding of small 
immune complexes.22 Correspondingly, FCGR3A was signifi -
cantly associated with RA in the subgroup of patients positive 
for either CCP or RF antibodies (OR 1.3, p=0.02) and with CCP 
antibodies in the meta-analysis (OR 1.3, p=0.004), but not those 
patients negative for each antibody. Further subgroup analyses 
Figure 1 (A, B) Meta-analysis of susceptibility to rheumatoid arthritis 
(RA) conferred by homozygosity for the FCGR3A-158 V allele compared 
with all other genotypes. CCP, cyclic citrullinated peptide.
Table 2 ORs for developing RA according to the presence or absence of homozygosity for the FCGR3A-158V and carriage of the HLA-DRB1 SE alleles
Cohort N
FCGR3A 158 genotype (HLA-DRB1 SE) p Value for departure 
from multiplicity*
p Value for departure 
from additivity†FForFV(+SE) FForFV(−SE) VV(+SE) VV(−SE)
Controls 1093 454 (0.42) 532 (0.49) 49 (0.04) 58 (0.05)
Total RA 2363 1577 (0.67) 484 (0.20) 226 (0.10) 76 (0.03) 0.7 0.4 (0.16)
OR (95% CI) 3.8 (3.6 to 4.5) 1.0 5.1 (3.6 to 7.1) 1.4 (1.0 to 2.1)
p Value <0.0001 – <0.0001 0.05
RF+ RA 1693 1203 (0.71) 272 (0.16) 175 (0.10) 43 (0.03) 0.8 0.3 (0.19)
OR (95% CI) 5.2 (4.3 to 6.2) 1.0 7.0 (4.9 to 9.9) 1.5 (1.0 to 2.2)
p Value <0.0001 – <0.0001 0.08
RF− RA  528 292 (0.55) 169 (0.32) 37 (0.07) 30 (0.06) 0.3 0.7
OR (95% CI) 2.0 (1.6 to 2.6) 1.0 2.4 (1.5 to 3.9) 1.6 (1.0 to 2.7)
p Value <0.0001 – 0.0002 0.04
CCP+ RA  899 655 (0.73) 127 (0.14) 98 (0.11) 19 (0.02) 1.0 0.2 (0.23)
OR (95% CI) 6.0 (4.8 to 7.6) 1.0 8.4 (5.7 to 12.4) 1.4 (0.8 to 2.4)
p Value <0.0001 – <0.0001 0.3
CCP− RA  316 152 (0.48) 130 (0.41) 13 (0.04) 21 (0.07) 0.1 0.2
OR (95% CI) 1.4 (1.0 to 1.8) 1.0 1.1 (0.5 to 2.1) 1.5 (0.8 to 2.6)
p Value  0.02 – 0.8 0.15
*Departure from a multiplicative joint effect on risk was tested using logistic regression, comparing a model with and without the interaction term using the likelihood ratio test.
†Attributable proportion (AP) is not calculated where the estimated joint effect is less than additive.
CCP, cyclic citrullinated peptide; RA, rheumatoid arthritis; RF, rheumatoid factor.
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cohort,6 but the study was underpowered to exclude the associa-
tion of FCGR3A copy number variation with disease.
It is likely that quantitative and qualitative analyses of all 
low-affi nity FCGR genes used in a combined approach will ulti-
mately be needed to fully elucidate the complex contribution of 
FCGR genetic variation to the pathogenesis of RA. This study 
highlights the inherent diffi culties in studying genes contained 
within segmental duplications and the fact that some genetic loci 
cannot be adequately assayed using modern high- throughput 
genotyping technologies. The study supports the ongoing inves-
tigation of the FCGR genetic locus in the pathogenesis of RA. 
Future efforts directed towards obtaining clearly defi ned patient 
cohorts with longitudinal clinical data from disease onset will 
ultimately determine whether this locus also contributes to dis-
ease severity and may serve as a prognostic marker.
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